Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,309 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
IPCA Labs reported a mixed Q1 FY26. Domestic formulation grew ~10% YoY, with chronic segment outpacing the market (15.1% vs 9.9%). Export branded formulations grew 10%, generics 15%, and API 12%. However, consolidated EBITDA margin declined marginally to 18.39% from 18.52% YoY, impacted by Unichem's lower profitability due to product mix shifts, one-time provisions (€14M EU penalty revaluation, Ireland closure costs), and weakness in Asia/Brazil. Standalone margins improved to 23.82% (vs 22.22% YoY) on better product mix. Management revised consolidated EBITDA margin guidance to +75bps (from +100bps) for FY26, while maintaining 9-10% revenue growth. Key risks include sustained pressure at Unichem, competitive intensity in UK/US, and slow recovery in subsidiaries (Onyx, Pisgah).
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained its earlier guidance of 9-10% topline growth for the full year, with Q1 performance in line.
- Revised from earlier guidance of +100bps to +75bps due to lower margins at Unichem, though standalone margins are tracking better.
- Standalone margins improved 1.6% YoY in Q1 (23.82% vs 22.22%), and management expects this trend to continue for the full year.
- IPCA expects to launch 4-5 products in the US market during FY26, with a steady cadence of 5-6 launches per year going forward.
Risks flagged
- Unichem's EBITDA margin declined due to loss of market share in high-margin US products, one-time provisions (EU penalty revaluation, Ireland closure), and weakness in Asia/Brazil. Management does not expect EBITDA growth in FY26.
- Management noted that the UK market was 'very fiercely competitive' with excess inventory and prices falling below cost for some products, impacting IPCA's UK business.
- Onyx (CDMO) reported a loss due to reduced project initiations; Pisgah (injectables) is still pre-commercialization. Management expects these to remain a drag for 1-2 years.
- Domestic CV therapy growth slowed to ~8% due to reorganization (adding 400 MRs). Recovery is expected but near-term growth may be subdued.
Key quotes
- Our guidance for the consolidated number was around 9 to 10% overall growth and overall margin increase by around 1% EBITDA margin... it may be around 75bps or so.
- In UK, it was a very tough kind of market scenario... some of the products were even selling below cost what has been shipped from India.
- Synergy business will still take around one year time... we have started now filing the products in various market.
Research modules